Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446267 | 0.86 | — | — | |
| SCHEMBL1445620 | 0.85 | PER2 (0.40) | PER2BRD4BRD2CRY2PIK3CD | |
| SCHEMBL11934366 | 0.80 | PER2 (0.42) | PER2BRD4BRD2CRY2PIK3CD | |
| SCHEMBL19383610 | 0.80 | PER2 (0.42) | PER2BRD4BRD2CRY2 | |
| SCHEMBL13208691 | 0.78 | PER2 (0.41) | PER2BRD4BRD2CRY2PIK3CD | |
| SCHEMBL1446202 | 0.78 | PER2 (0.41) | PER2BRD4BRD2CRY2PIK3CD | |
| SCHEMBL1446053 | 0.77 | PER2 (0.40) | PER2BRD4BRD2CRY2PIK3CD | |
| SCHEMBL1446205 | 0.77 | PER2 (0.43) | PER2BRD4BRD2CRY2PIK3CD | |
| SCHEMBL1446055 | 0.77 | PER2 (0.40) | PER2BRD4BRD2CRY2PIK3CD | |
| SCHEMBL82580 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492536-B1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-09 | — | — | EP | claimed |
| CN-101648947-A | 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM PHARMA DE | 2010-02-17 | — | — | CN | claimed |
| US-7456189-B2 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-25 | — | — | US | claimed |
| US-7119084-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-10 | — | — | US | claimed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | claimed |
| CN-1642552-A | 4- (N-phenylamino) -quinazolines/quinolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-07-20 | — | — | CN | claimed |
| US-20050070560-A1 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-31 | — | — | US | claimed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| US-8343982-B2 | Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-20110077246-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2011-03-31 | — | — | US | disclosed |
| US-7910731-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2011-03-22 | — | — | US | disclosed |
| CN-1642552-B | 4- (N-phenylamino) -quinazolines/quinolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM PHARMA | 2010-05-12 | — | — | CN | disclosed |
| CN-101648947-A | 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM PHARMA DE | 2010-02-17 | — | — | CN | disclosed |
| US-7119084-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-10 | — | — | US | disclosed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | disclosed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | disclosed |
| CN-1642552-A | 4- (N-phenylamino) -quinazolines/quinolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-07-20 | — | — | CN | disclosed |
| US-20050070560-A1 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077246-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME | CYP11B2, CYP11B1, PKD1 | PER2 4734/4885BRD4 108/4885BRD2 437/4885 |
| US-20050070560-A1 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation | BPHL, BRDT, PKD1 | PER2 3136/4885BRD4 49/4885BRD2 683/4885 |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | PER2 4749/4885BRD4 85/4885BRD2 353/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | PER2 3823/4885BRD4 1679/4885BRD2 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.